Log in
Enquire now
‌

US Patent 11254747 Covalent diabodies and uses thereof

Patent 11254747 was granted and assigned to MacroGenics on February, 2022 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Applicant
MacroGenics
MacroGenics
Current Assignee
MacroGenics
MacroGenics
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
11254747
Date of Patent
February 22, 2022
Patent Application Number
15911869
Date Filed
March 5, 2018
Patent Citations
‌
US Patent 10131713 HER2/neu-specific antibodies and methods of using same
‌
US Patent 10150812 CD3-binding molecules capable of binding to human and non-human CD3
‌
US Patent 10160806 Covalently bonded diabodies having immunoreactivity with PD-1 and LAG-3, and methods of use thereof
‌
US Patent 10280231 Compound targeting IL-23A and B-cell activating factor (BAFF) and uses thereof
‌
US Patent 10344092 Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
‌
US Patent 10479831 BCR-complex-specific antibodies and methods of using same
‌
US Patent 10501552 Multivalent molecules comprising DR5-binding domains
‌
US Patent 10577422 PD-1-binding molecules and methods of use thereof
...
Patent Primary Examiner
‌
Brad Duffy
Patent abstract

The present invention is directed to diabody molecules and uses thereof in the treatment of a variety of diseases and disorders, including immunological disorders, infectious disease, intoxication and cancers. The diabody molecules of the invention comprise two polypeptide chains that associate to form at least two epitope binding sites, which may recognize the same or different epitopes on the same or differing antigens. Additionally, the antigens may be from the same or different molecules. The individual polypeptide chains of the diabody molecule may be covalently bound through nonpeptide bond covalent bonds, such as, but not limited to, disulfide bonding of cysteine residues located within each polypeptide chain. In particular embodiments, the diabody molecules of the present invention further comprise an Fc region, which allows antibody like functionality to engineered into the molecule.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 11254747 Covalent diabodies and uses thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us